GET DAILY SIGNALSADC Therapeutics (ADCT) Delivers Q3 Revenue Beat With Tighter Cost Controls
Key Takeaways
- ADC Therapeutics (ADCT) reported third quarter 2026 total revenue of $21.72 million, beating the consensus estimate of roughly $18.7 million.
- Net product revenue from its lead therapy ZYNLONTA reached about $21.0 million, up from $15.8 million in the same period a year earlier.
- The company posted a net loss of $0.16 per share, narrower than the roughly $0.21 loss analysts had expected, and an adjusted (non-GAAP) loss of just $0.06 per share.
- Total operating expenses fell 24% year over year, reflecting disciplined cost management and lower research and development spending.
- Cash and cash equivalents stood at $189.2 million, which management says supports an expected runway into 2029.
Earnings Context and Why It Matters
ADC Therapeutics is a commercial-stage biotech focused on antibody drug conjugates (ADCs), a class of targeted cancer therapies that link an antibody to a cancer-killing payload. Its lead product, ZYNLONTA, is approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of therapy. The third quarter report matters because it shows whether ZYNLONTA sales can grow while the company prepares pivotal clinical readouts aimed at expanding into earlier treatment lines and larger patient populations. With a shrinking cash balance and rising development costs, investors also watch expense discipline and the cash runway closely. The results confirm a company executing on commercial stability while awaiting catalysts that could reshape its long-term revenue trajectory. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the quarter ended September 30, 2026, ADC Therapeutics reported total revenue of $21.72 million, up from $16.43 million a year earlier and above the consensus estimate of approximately $18.7 million. ZYNLONTA net product revenue was about $21.0 million, compared with $15.8 million in the prior-year period, driven primarily by higher sales volume. License and royalty revenue contributed $0.71 million.
The company reported a net loss of $25.3 million, or $0.16 per share, versus a net loss of $41.0 million, or $0.30 per share, in the third quarter of 2025. On a non-GAAP (adjusted) basis, the net loss was $8.8 million, or $0.06 per share, compared with $25.5 million, or $0.19 per share, a year earlier. Both figures beat analyst expectations. Total operating expenses declined 24% year over year to $36.1 million, with adjusted operating expenses down 29%, driven mainly by lower research and development spending. As of September 30, 2026, cash and cash equivalents were $189.2 million, down from $261.3 million at the end of 2025, with management guiding to a runway into 2029.
Market Reaction and Investor Sentiment
Investor sentiment heading into the report had been improving, with ADCT shares up more than 50% over the trailing three months, though the stock remains sharply lower over the past year. The earnings beat on both revenue and the bottom line reinforces a narrative of stabilizing ZYNLONTA sales and tighter cost control. Still, the market's longer-term focus remains on clinical catalysts rather than a single quarter's results. Sentiment is likely to stay tied to data readouts from the LOTIS-7 combination study, potential regulatory progress in Japan, and presentations at the American Society of Hematology (ASH) annual meeting, where management has indicated multiple abstracts have been accepted.
Forward Outlook and Key Factors to Monitor
The most important upcoming catalyst for ADC Therapeutics is clinical data. Management has highlighted multiple abstracts accepted for presentation at ASH, including full results from the LOTIS-7 study, which evaluates ZYNLONTA in combination with another agent in B-cell malignancies. These data could support expanded use of ZYNLONTA and strengthen the company's growth case.
Investors should also watch regulatory and commercial milestones in Japan, where a potential approval would open a new geography for the product. On the financial side, the key monitor is whether expense discipline continues while the company funds late-stage development. Lower research and development spending has narrowed losses, but sustaining that trend without delaying important trials will be essential.
Finally, the balance sheet remains a focal point. With $189.2 million in cash and a stated runway into 2029, the company has reduced near-term financing risk, but continued cash burn and the timing of clinical milestones will shape how comfortable investors are with that cushion. As ZYNLONTA sales growth and data readouts unfold, the market will look for evidence that the company can convert pipeline progress into a meaningfully larger commercial opportunity.
Exploring AI Tools for Stock Analysis
In my own research process, I find Tickeron’s AI Screener particularly useful for quickly filtering opportunities across biotech names like ADCT. It lets me apply technical patterns, fundamentals, and AI signals to surface comparable ideas without spending hours on manual screens. This approach helps me stay focused on the data that actually moves the needle for names in this space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ADCT sees MACD Histogram just turned negative
ADCT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 52 instances where the indicator turned negative. In 48 of the 52 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ADCT moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 19 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ADCT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 67 cases where ADCT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on ADCT as a result. In 76 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
ADCT moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +11.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADCT advanced for three days, in 183 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 139 of 151 cases where ADCT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.884) is normal, around the industry mean (7.271). P/E Ratio (-2.724) is within average values for comparable stocks, (0.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (1.967) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ADCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement